Literature DB >> 30617134

Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes.

Amrei Binzer-Panchal1, Elin Hardell2, Anders Isaksson1, Joseph W Carlson3, Björn Viklund1, Mehran Ghaderi2, Tjalling Bosse4, Marisa R Nucci5, Cheng-Han Lee6, Nina Hollfelder1, Pádraic Corcoran1, Jordi Gonzalez-Molina2,7, Lidia Moyano-Galceran7, Debra A Bell8, John K Schoolmeester8, Anna Måsbäck9, Gunnar B Kristensen10, Ben Davidson11, Kaisa Lehti7,12.   

Abstract

PURPOSE: Undifferentiated uterine sarcomas (UUS) are rare, extremely deadly, sarcomas with no effective treatment. The goal of this study was to identify novel intrinsic molecular UUS subtypes using integrated clinical, histopathologic, and molecular evaluation of a large, fully annotated, patient cohort. EXPERIMENTAL
DESIGN: Fifty cases of UUS with full clinicopathologic annotation were analyzed for gene expression (n = 50), copy-number variation (CNV, n = 40), cell morphometry (n = 39), and protein expression (n = 22). Gene ontology and network enrichment analysis were used to relate over- and underexpressed genes to pathways and further to clinicopathologic and phenotypic findings.
RESULTS: Gene expression identified four distinct groups of tumors, which varied in their clinicopathologic parameters. Gene ontology analysis revealed differential activation of pathways related to genital tract development, extracellular matrix (ECM), muscle function, and proliferation. A multivariable, adjusted Cox proportional hazard model demonstrated that RNA group, mitotic index, and hormone receptor expression influence patient overall survival (OS). CNV arrays revealed characteristic chromosomal changes for each group. Morphometry demonstrated that the ECM group, the most aggressive, exhibited a decreased cell density and increased nuclear area. A cell density cutoff of 4,300 tumor cells per mm2 could separate ECM tumors from the remaining cases with a sensitivity of 83% and a specificity of 94%. IHC staining of MMP-14, Collagens 1 and 6, and Fibronectin proteins revealed differential expression of these ECM-related proteins, identifying potential new biomarkers for this aggressive sarcoma subgroup.
CONCLUSIONS: Molecular evaluation of UUS provides novel insights into the biology, prognosis, phenotype, and possible treatment of these tumors. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30617134     DOI: 10.1158/1078-0432.CCR-18-2792

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  5 in total

1.  Uterine leiomyosarcoma diagnosis after treatment of presumed uterine fibroid with the high-intensity focused ultrasound: a case description.

Authors:  Sha Wang; Hua Duan; Xiaoying Zhang; Bohan Li
Journal:  Quant Imaging Med Surg       Date:  2022-06

2.  Sarcoma Tumor Microenvironment.

Authors:  Panagiotis Tsagozis; Jordi Gonzalez-Molina; Anna-Maria Georgoudaki; Kaisa Lehti; Joseph Carlson; Andreas Lundqvist; Felix Haglund; Monika Ehnman
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 3.  MMP14 in Sarcoma: A Regulator of Tumor Microenvironment Communication in Connective Tissues.

Authors:  Jordi Gonzalez-Molina; Silvia Gramolelli; Zehuan Liao; Joseph W Carlson; Päivi M Ojala; Kaisa Lehti
Journal:  Cells       Date:  2019-08-28       Impact factor: 6.600

4.  Pan-Cancer Molecular Patterns and Biological Implications Associated with a Tumor-Specific Molecular Signature.

Authors:  Darío Rocha; Iris A García; Aldana González Montoro; Andrea Llera; Laura Prato; María R Girotti; Gastón Soria; Elmer A Fernández
Journal:  Cells       Date:  2020-12-31       Impact factor: 6.600

5.  Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing.

Authors:  Martee L Hensley; Shweta S Chavan; Mark T A Donoghue; David M Hyman; David B Solit; Rajmohan Murali; Robert Soslow; Sarah Chiang; Achim A Jungbluth; Chaitanya Bandlamudi; Preethi Srinivasan; William D Tap; Evan Rosenbaum; Barry S Taylor
Journal:  Clin Cancer Res       Date:  2020-04-16       Impact factor: 13.801

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.